Efficacy, safety, and tolerability of lysergic acid diethylamide for the treatment of depressive symptoms: A meta-analysis and systematic review
Andreea Chiorean, Helena K. Kim, Andrew Lustig, Muhammad Ishrat HusainBackground:
Since the Food and Drug Administration designated lysergic acid diethylamide (LSD) as a “breakthrough” treatment for generalized anxiety disorder, accumulating randomized clinical trials (RCTs) evaluating LSD’s anxiolytic effects have also reported improved depression symptoms. Evaluating the safety and efficacy of LSD in treating depression symptoms is warranted.
Methods:
MEDLINE/PubMED, Embase, and PsychINFO were searched from inception to December 9, 2025. RCTs evaluating efficacy of LSD on depression symptoms in adults with mental disorders were included. Cochrane Risk of Bias Tool 2.0 and χ
2
and
Results:
Of 465 screened studies, 5 RCTs met selection criteria (
Conclusion:
Our findings suggest that LSD, with and without psychological support, reduces depression scores in clinical populations. This review is limited by small sample size. Future well-designed RCTs are needed to establish the efficacy and safety of LSD in managing depression.